1 results match your criteria: "University of Groningen The Netherlands a.s.s.domling@rug.nl.[Affiliation]"
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.
RSC Med Chem
December 2020
Department of Drug Design, University of Groningen The Netherlands
Article Synopsis
- The rapid increase in COVID-19 cases is leading to higher death rates and a struggling global economy.
- Drug discovery is a lengthy process, making drug repurposing a more viable short-term solution for combating the pandemic, while vaccinations serve as a middle-term option.
- The study identifies boceprevir, an existing HCV drug, as a potential inhibitor of SARS-CoV-2's main protease, suggesting its promise for repurposing in COVID-19 treatment.